Trial NCT03810313

View at ClinicalTrials.gov 
Org. Study IDs: CRTH258C2302
Secondary IDs: 2018-001788-21

Last trial update was posted on 2023-01-30

MeSH Interventions

Aflibercept

MeSH Conditions

Macular Edema Retinal Vein Occlusion Vision Disorders Vision, Low

Other Conditions

Central Retinal Vein Occlusion

Stopping Reasons

Study was terminated by sponsor due to increased incidences of adverse events of special interest (intraocular inflammation including retinal vasculitis, and retinal vascular occlusion), in patients dosed every 4 weeks beyond 3 initial doses.

Limitations And Caveats

N/A

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID